nadolol has been researched along with raltegravir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Álvarez, M; Cheng, X; De Clercq, E; Gao, P; Liu, X; Luczkowiak, J; Menéndez-Arias, L; Pannecouque, C; Song, S; Sun, L; Zhan, P | 1 |
1 review(s) available for nadolol and raltegravir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for nadolol and raltegravir
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase.
Topics: Anti-HIV Agents; Caco-2 Cells; Cell Line; Cell Membrane Permeability; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; HIV Integrase; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Models, Molecular; Molecular Structure; Quinazolinones; Ribonuclease H, Human Immunodeficiency Virus; Structure-Activity Relationship | 2019 |